Category: Antidiabetic (Biguanide) • Catalog ID: GLYCOMET-500 • Reviewed by MediMatch Clinical Pharmacology Review Board
Glycomet 500 Tablet — Metformin Hydrochloride 500mg
Evidence-based clinical monograph for Glycomet 500 Tablet, formulated with active pharmaceutical ingredient Metformin Hydrochloride 500mg and manufactured by USV Private Limited. Includes FDA/EMA/WHO international nomenclature cross-walk, 6-point patient safety matrix, and multi-currency generic reference pricing.
1. Quick Facts & Global Nomenclature Cross-Walk (WHO INN / US FDA USAN / UK BNF)
| Brand Name | Glycomet 500 (Tablet) |
| Active Salt (WHO INN) | Metformin Hydrochloride 500mg |
| U.S. FDA USAN / Orange Book | Metformin Hydrochloride 500mg |
| UK BNF / EMA BAN | Metformin Hydrochloride 500mg |
| Global Commercial Brand Equivalents by Region | 🇺🇸 USA/Canada: Glycomet 500 US Equivalent (FDA Orange Book) (Glycomet 500 Health Canada DPD Equivalent) • 🇬🇧 UK/Europe: Glycomet 500 UK/EU Equivalent (BNF / EMA) • 🇦🇺 Australia: Glycomet 500 Australia TGA / PBS Equivalent • 🇦🇪 UAE/GCC: Glycomet 500 UAE MOHAP / DHA Equivalent • 🇮🇳 India: Glycomet 500 / PMBJP Jan Aushadhi |
| Same-Salt Commercial Brand Substitutes | Glycomet 500Metfor 500Okamet 500Riomet 500Glyciphage 500 |
| Dosage Form & Route | Tablet (Oral Systemic Administration) |
| Manufacturer | USV Private Limited |
| Branded MRP vs Jan Aushadhi Generic | MRP ₹24.00 vs Jan Aushadhi ₹4.50 • Save ₹19.50 (81% Off) |
3. Clinical Indications, Mechanism of Action & Pharmacokinetics
Glycomet 500 (Tablet) containing Metformin Hydrochloride 500mg is clinically indicated for the management and treatment of:
- Type 2 Diabetes Mellitus: Targeted therapeutic efficacy via Antidiabetic (Biguanide) pathway modulation.
- PCOS (Polycystic Ovary Syndrome): Targeted therapeutic efficacy via Antidiabetic (Biguanide) pathway modulation.
- Insulin Resistance: Targeted therapeutic efficacy via Antidiabetic (Biguanide) pathway modulation.
Mechanism of Action & Pharmacokinetics: Following administration as a tablet, Metformin Hydrochloride 500mg undergoes calibrated systemic absorption and hepatic/renal clearance in accordance with WHO-GMP, USP, and Indian Pharmacopoeia (IP) dissolution and bioequivalence standards.
4. Standard Dosage Table, Administration & Storage Guidelines
Dosage & Administration Reference Table: Always follow your physician's prescription for Glycomet 500 Tablet (ISMP safety normalized):
| Prescription Sig Code |
Administration Schedule |
Meal & Timing Guidance |
Clinical Patient Group |
| OD (Once Daily) |
1 unit (Tablet) every 24 hours |
With or after meals |
Adults |
| BD / BID (Twice Daily) |
1 unit (Tablet) every 12 hours (Morning & Night) |
With or after meals |
Adults |
| TDS / TID (Thrice Daily) |
1 unit (Tablet) every 8 hours (if prescribed) |
Maintain minimum 6–8 hour spacing |
As directed by registered physician |
Storage & Stability: Store Glycomet 500 (Tablet) in a cool, dry place below 30°C (86°F) away from direct sunlight, heat, and moisture. Keep blister strips sealed until administration and out of reach of children.
8. Frequently Asked Questions (Glycomet 500 Tablet)
Q: What is Glycomet 500 Tablet (Metformin Hydrochloride 500mg) used for?
Glycomet 500 Tablet contains Metformin Hydrochloride 500mg and is manufactured by USV Private Limited. It is primarily indicated for Type 2 Diabetes Mellitus, PCOS (Polycystic Ovary Syndrome), Insulin Resistance under the Antidiabetic (Biguanide) therapeutic class.
Q: Is a generic equivalent or Jan Aushadhi substitute available for Glycomet 500 Tablet?
Yes, bioequivalent generic Metformin Hydrochloride 500mg (Tablet) is available globally ($1.20 USD NADAC / £0.95 UK NHS Tariff) and at PMBJP Jan Aushadhi Kendras in India for ₹4.50 per strip, saving 81% compared to branded MRP ₹24.00.
Q: What is the dosage instruction for Glycomet 500 Tablet?
Common dosage frequencies for Glycomet 500 (Tablet) are OD (once daily), BD/BID (twice daily), or TDS/TID (thrice daily) as prescribed by your physician. With or after meals
Q: Is Glycomet 500 Tablet safe during pregnancy, breastfeeding, or with alcohol?
Pregnancy guidance: CAUTION — CONSULT DOCTOR (Use during pregnancy only if clearly needed and prescribed by an obstetrician after risk-benefit evaluation (FDA PLLR / TGA clinical guidance).) Alcohol guidance: AVOID (Avoid alcohol consumption during therapy to prevent additive hepatotoxicity, gastric irritation, or central nervous system sedation.)